Artificial Intelligence
AAV Vectors in Gene Therapy Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 70+ Companies Working in the Domain
<!– Name:DistributionId Value:8826848 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value: –> <!– Name:CustomerId Value:1204938 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:0c87335c-fa1d-4f74-8990-0aeea8732948 –>
New York, USA, April 27, 2023 (GLOBE NEWSWIRE) — AAV Vectors in Gene Therapy Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 70+ Companies Working in the Domain
AAV-vector is currently being tested to cure diseases that were previously thought to be nearly impossible to treat. The best example is the involvement of AVV-vector gene therapy in treating neurological disorders like Spinal Muscular Atrophy, Huntington’s disease, Parkinson’s disease, Alzheimer’s Disease, etc. Either little is known about the exact cause of these diseases, or like in the case of Alzheimer’s disease, there are several competing hypotheses behind the cause. These neurodegenerative diseases represent a particularly devastating health problem for which a significant unmet medical need exists. AAV-vector gene therapy has already shown benefits in treating many diseases, but still, several unanswered questions need to be addressed. Current results are promising and suggest that investigators have now defined a population of patients that can expect long-lasting expression of a donated gene from an AAV vector.
DelveInsight’s ‘AAV Vectors in Gene Therapy Pipeline Insight 2023‘ report provides comprehensive global coverage of available pipeline AAV vectors in gene therapy in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the AAV vectors in gene therapy pipeline domain.
Key Takeaways from the AAV Vectors in Gene Therapy Pipeline Report
- DelveInsight’s AAV vectors in gene therapy pipeline report depicts a robust space with 70+ active players working to develop 210+ pipeline therapies.
- Key AAV vectors in gene therapy companies such as Gensight Biologics, PTC therapeutics, uniQure, Pfizer, Ultragenyx Pharmaceutical, Sarepta therapeutics, Neurophth Therapeutics, LYSOGENE, Gyroscope Therapeutics, Nanoscope Therapeutics, Homology medicines, Ultragenyx Pharmaceutical, Passage Bio, Astellas Pharma, Aspa therapeutics, Adrenas Therapeutics, ESTEVE, Sio Gene Therapies, Amicus therapeutics, 4D Molecular therapeutics, Taysha Gene Therapies, Atsena Therapeutics, BioMarin Pharmaceutical, Abeona Therapeutics, REGENXBIO, uniQure, Taysha Gene Therapies, Asklepios BioPharmaceutical, Sarepta Therapeutics, Abeona Therapeutics, Forge Biologics, Sangamo therapeuics, Bayer, LogicBio therapeutics, Solid Biosciences, Applied Genetic Technologies, Spark therapeuics (Roche), Eli lilly and company, Lexeo Therapeutics, Spark therapeutics, Gensight Biologics, Alcyone Lifesciences, MeiraGTx, Audentes therapeutics, Vivet Therapeutics, Astellas Gene Therapies, Homology Medicines, Adverum Biotechnologies, Libella Gene Therapeutics, Rocket Pharmaceuticals, Brain Neurotherapy Bio, Inc., Ocugen, Asklepios BioPharmaceutical, Neurogene, Jaguar Gene Therapy, LLC, Axovia Therapeutics, Coave therapeutics, Novartis, Arctos medical, Novartis, Vedere Bio, REGENXBIO Inc., StrideBio, Abeona therapeutics, Sanofi, Sirion therapeutics, Capsida Biotherapeutics, Kriya therapeutics, Neurophth, Poseida Therapeutics, BridgeBio Pharma, DiNAQOR, Biomarin, ViGeneron, AskBio, Selecta Biosciences, Prevail therapeutics, Intas Pharmaceuticals, Tenaya Therapeutics, Scout Bio therapeutics, Ocugen, Oyster Point pharmaceuticals, Cyprium Therapeutics, Solid Biosciences, Amicus Therapeutics, Coave therapeutics, AvantiBio, Voyager Therapeutics, Pfizer, Aruvant Sciences, Alcyone Lifesciences, Gene Therapy Research Institution Co., Ltd., and others are evaluating new candidates to improve the treatment landscape.
- Promising AAV vectors in gene therapy in pipeline such as GS010, Eladocagene exuparvovec, DTX401, AAV5-RPGR, Fidanacogene elaparvovec, AMT 061, Giroctocogene fitelparvovec, UX701, RGX-314, SPK-8011, SRP-9001, NFS-01, LYS-SAF302, GT005, MCO-010, HMI-102, DTX301, PBGM01, PBKR03, FLT180a, PBFT02, AT702, BBP-812, BBP-631, EGT-101, AT-GTX-501, AT-GTX-502, AAV2-hCHM, 4D-125, BMN 331, TSHA-118, SAR439483, BMN 307, ABO-102, CTx-PDE6b, RGX-121, RGX-111, AMT-130, TSHA-120, TSHA-101, AAV2/8-LSPhGAA, AAV2-GDNF, SRP-9003, ABO-101, SRP-9004, FBX-101, Isaralgagene civaparvovec (ST-920), (BAY-2599023), LB-001, SGT-001, rAAV2tYF-PR1.7-hCNGB3, AGTC-402, SPK-8016, PR001, PR006, 4D-310, LX1004, SPK-3006, GS030, ACTX 401, AAV- CNGA3, AAV-CNGB3, AT132, rAAVrh74.MCK.GALGT2, scAAV9.U7.ACCA, VTX 801, TAK 754, AskBio009, AT 845, SRP-6004, HMI-203, ADVM-022, AAV-hTERT, LX1001, RP-A501, AAV2-GDNF gene therapy, 4D 110, 4D-710, OCU400, LION-10, AAV gene therapies, 4D-150, JAG101, JAG201, AXV101, CTx-ABCA4, Optogenetic AAV gene therapy, Research programme: AAV ocular gene therapy, RGX-202, RGX-181, RGX-381, AMT-210, AMT-161, AMT-191, AMT-150, STRX-210, STRX-110, STRX-230, ABO-201, SRP-9005, SRP-9006, AAV gene therapy, Research programme: adeno associated virus based gene therapies, KT-A112, KT-A522, KT-A832, NFS-02, NFS- 04, NFS-05, NFS-10, P-OTC-101, BBP-815, BBP-818, DiNA-001, EGT-201, EGT-301, VG901, VG801, MMA-101, FLT210, FLT201, PR004, AAV-FIX, AAV-FVIII, AAV-AntiVEGF, TN-201, PKP2 PROGRAM, DWORF GENE THERAPY PROGRAM, SB-004, OCU410, ETF™ Gene Therapy, TSHA-102, LX2020, LX2021, LX2022, LX1020, LX1021, AMT-240, AMT-260, UX810, STRX-310, STRX-330, AAV-ATP7A Gene Therapy, SGT-003, TSHA-119, TSHA-104, TSHA-112, TSHA-106, TSHA-103, TSHA-105, TSHA-111-LAFORIN, TSHA-111-MALIN, Research programme: AAV based gene therapies, CTx-GBA1, CTx-FUS, Program: XLRS, Program: USH1B, KT-A281, KT-A252, KT-A261, AVB-202, TRACERᵀᴹ AAV Capsids, AAV gene therapies, AT GTX 701, LX2006, ARU-2801, Anc 80L65-arylsulfatase A, Anc 80L65-trastuzumab, ACTX 101, JAG301, NFS-07, NFS-09, NFS-11, NFS-12, NFS-13, STRX-220, STRX-240, vgAAV, AAV-SMN1, AAV-DMD, AAV.103, AAV.104, DINA-002, DINA-003, DINA-004, STRX-340, TSHA-113, TSHA-115, TSHA-114, TSHA-116, TSHA-117, TSHA-107, TSHA-108, TSHA-109, and others are under different phases of AAV vectors in gene therapy clinical trials.
- In January 2023, Rocket Pharmaceuticals announced the addition of RP-A601 to Rocket’s cardiac gene therapy portfolio as well as anticipated highlights for the year ahead across the Company’s world-class pipeline of lentiviral and AAV gene therapy programs targeting rare hematologic and cardiovascular diseases.
- In October 2022, Astellas Pharma and Taysha Gene Therapies, Inc. announced a strategic investment to support the advancement of Taysha’s adeno-associated virus (AAV) gene therapy development programs for the treatment of Rett syndrome and GAN.
Request a sample and discover the recent advances in AAV vectors in gene therapy @ AAV Vectors in Gene Therapy Pipeline Report
The AAV vectors in gene therapy pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage AAV vectors in gene therapy, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the AAV vectors in gene therapy clinical trial landscape.
AAV Vectors in Gene Therapy Overview
The Adeno-associated viral (AAV) vector appears to be the safest and most effective vehicle for delivering the genes of interest, and it can maintain long-term gene and protein expression following a single injection of the vector. AAV vectors are the most widely used viral vectors for gene delivery to treat a wide range of human diseases. Recent advances in developing clinically desirable AAV capsids, optimizing genome designs, and harnessing revolutionary biotechnologies have all contributed significantly to the field’s growth. Preclinical and clinical successes in AAV-mediated gene replacement, gene silencing, and gene editing have contributed to AAV’s popularity as an ideal therapeutic vector, with only a few AAV-based therapeutics gaining regulatory approval in Europe and the United States.
Recombinant AAVs (rAAV) are now used for in vivo gene therapy delivery. The groundbreaking effort and outcomes of gene therapy led to the approval of Glybera, the first gene therapy approved by the European Medicines Agency (EMA) in 2012 to treat lipoprotein lipase deficiency. Luxturna received regulatory approval from the US Food and Drug Administration after a few years (FDA). The approval of these therapies was a watershed moment for researchers developing successful gene therapy protocols for inherited human disorders.
Learn more about the AAV vectors for gene therapy in clinical trials @ AAV Vectors for Gene Therapy
A snapshot of the AAV Vectors in Gene Therapy Pipeline Drugs mentioned in the report:
| Drugs | Company | Indication | Phase | RoA |
| GS010 | Gensight Biologics | Leber’s hereditary optic atrophy | Preregistration | Intravitreal |
| DTX401 | Ultragenyx Pharmaceutical | Glycogen storage disease type I | Phase III | Intravenous |
| AAV5-RPGR | MeiraGTx | Retinitis pigmentosa | Phase III | Subretinal |
| RGX-314 | REGENXBIO | Wet age-related macular degeneration | Phase III | Subretinal |
| SPK-8011 | Spark Therapeutics | Hemophilia A | Phase III | Intravenous |
| NFS-01 | Neurophth | Leber’s hereditary optic atrophy | Phase III | Intravitreal |
| GT 005 | Gyroscope Therapeutics | Dry age-related macular degeneration | Phase II | Intraocular |
Discover more about AAV vectors in gene therapy in development @ AAV Vectors in Gene Therapy Clinical Trials
AAV Vectors in Gene Therapy Therapeutics Assessment
The AAV vectors in gene therapy pipeline report proffers an integral view of the emerging novel AAV vectors in gene therapy segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the AAV Vectors in Gene Therapy Pipeline Report
- Coverage: Global
- AAV Vectors in Gene Therapy Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- AAV Vectors in Gene Therapy Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- AAV Vectors in Gene Therapy Therapeutics Assessment By Route of Administration: Intracerebral, Intracerebroventricular, Intracisternal, Intramuscular, Intraocular, Intrapancreatic, Intrastriatal, Intrathecal, Intravenous, Intravitreous, Introvitinreous, Oral, Parenteral, Retinal, Intra-arterial
- AAV Vectors in Gene Therapy Therapeutics Assessment By Molecule Type: Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy
- Key AAV Vectors in Gene Therapy Companies: BioMarin Pharmaceutical, Gensight Biologics, PTC therapeutics, uniQure, Pfizer, Ultragenyx Pharmaceutical, Biogen, Sarepta therapeutics, Neurophth Therapeutics, LYSOGENE, Gyroscope Therapeutics, Nanoscope Therapeutics, Homology medicines, Ultragenyx Pharmaceutical, Passage Bio, Astellas Pharma, Aspa therapeutics, Adrenas Therapeutics, ESTEVE, Sio Gene Therapies, Amicus therapeutics, 4D Molecular therapeutics, Taysha Gene Therapies, Atsena Therapeutics, BioMarin Pharmaceutical, Abeona Therapeutics, REGENXBIO, uniQure, Taysha Gene Therapies, Asklepios BioPharmaceutical, Sarepta Therapeutics, Abeona Therapeutics, Forge Biologics, Sangamo therapeuics, Bayer, LogicBio therapeutics, Solid Biosciences, Applied Genetic Technologies, Spark therapeuics (Roche), Eli lilly and company, Lexeo Therapeutics, Spark therapeutics, Gensight Biologics, Alcyone Lifesciences, MeiraGTx, Audentes therapeutics, Vivet Therapeutics, Astellas Gene Therapies, Homology Medicines, Adverum Biotechnologies, Libella Gene Therapeutics, Rocket Pharmaceuticals, Brain Neurotherapy Bio, Inc., Ocugen, Asklepios BioPharmaceutical, Neurogene, Jaguar Gene Therapy, LLC, Axovia Therapeutics, Coave therapeutics, Novartis, Arctos medical, Novartis, Vedere Bio, REGENXBIO Inc., StrideBio, Abeona therapeutics, Sanofi, Sirion therapeutics, Capsida Biotherapeutics, Kriya therapeutics, Neurophth, Poseida Therapeutics, BridgeBio Pharma, DiNAQOR, Biomarin, ViGeneron, AskBio, Selecta Biosciences, Prevail therapeutics, Intas Pharmaceuticals, Tenaya Therapeutics, Scout Bio therapeutics, Ocugen, Oyster Point pharmaceuticals, Cyprium Therapeutics, Solid Biosciences, Amicus Therapeutics, Coave therapeutics, AvantiBio, Voyager Therapeutics, Pfizer, Aruvant Sciences, Alcyone Lifesciences, Gene Therapy Research Institution Co., Ltd., and others
- Key AAV Vectors in Gene Therapy in Pipeline: GS010, Eladocagene exuparvovec, DTX401, AAV5-RPGR, Fidanacogene elaparvovec, AMT 061, Giroctocogene fitelparvovec, UX701, RGX-314, SPK-8011, SRP-9001, NFS-01, LYS-SAF302, GT005, MCO-010, HMI-102, DTX301, PBGM01, PBKR03, FLT180a, PBFT02, AT702, BBP-812, BBP-631, EGT-101, AT-GTX-501, AT-GTX-502, AAV2-hCHM, 4D-125, BMN 331, TSHA-118, SAR439483, BMN 307, ABO-102, CTx-PDE6b, RGX-121, RGX-111, AMT-130, TSHA-120, TSHA-101, AAV2/8-LSPhGAA, AAV2-GDNF, SRP-9003, ABO-101, SRP-9004, FBX-101, Isaralgagene civaparvovec (ST-920), (BAY-2599023), LB-001, SGT-001, rAAV2tYF-PR1.7-hCNGB3, AGTC-402, SPK-8016, PR001, PR006, 4D-310, LX1004, SPK-3006, GS030, ACTX 401, AAV- CNGA3, AAV-CNGB3, AT132, rAAVrh74.MCK.GALGT2, scAAV9.U7.ACCA, VTX 801, TAK 754, AskBio009, AT 845, SRP-6004, HMI-203, ADVM-022, AAV-hTERT, LX1001, RP-A501, AAV2-GDNF gene therapy, 4D 110, 4D-710, OCU400, LION-10, AAV gene therapies, 4D-150, JAG101, JAG201, AXV101, CTx-ABCA4, Optogenetic AAV gene therapy, Research programme: AAV ocular gene therapy, RGX-202, RGX-181, RGX-381, AMT-210, AMT-161, AMT-191, AMT-150, STRX-210, STRX-110, STRX-230, ABO-201, SRP-9005, SRP-9006, AAV gene therapy, Research programme: adeno associated virus based gene therapies, KT-A112, KT-A522, KT-A832, NFS-02, NFS- 04, NFS-05, NFS-10, P-OTC-101, BBP-815, BBP-818, DiNA-001, EGT-201, EGT-301, VG901, VG801, MMA-101, FLT210, FLT201, PR004, AAV-FIX, AAV-FVIII, AAV-AntiVEGF, TN-201, PKP2 PROGRAM, DWORF GENE THERAPY PROGRAM, SB-004, OCU410, ETF™ Gene Therapy, TSHA-102, LX2020, LX2021, LX2022, LX1020, LX1021, AMT-240, AMT-260, UX810, STRX-310, STRX-330, AAV-ATP7A Gene Therapy, SGT-003, TSHA-119, TSHA-104, TSHA-112, TSHA-106, TSHA-103, TSHA-105, TSHA-111-LAFORIN, TSHA-111-MALIN, Research programme: AAV based gene therapies, CTx-GBA1, CTx-FUS, Program: XLRS, Program: USH1B, KT-A281, KT-A252, KT-A261, AVB-202, TRACERᵀᴹ AAV Capsids, AAV gene therapies, AT GTX 701, LX2006, ARU-2801, Anc 80L65-arylsulfatase A, Anc 80L65-trastuzumab, ACTX 101, JAG301, NFS-07, NFS-09, NFS-11, NFS-12, NFS-13, STRX-220, STRX-240, vgAAV, AAV-SMN1, AAV-DMD, AAV.103, AAV.104, DINA-002, DINA-003, DINA-004, STRX-340, TSHA-113, TSHA-115, TSHA-114, TSHA-116, TSHA-117, TSHA-107, TSHA-108, TSHA-109, and others
To know more about AAV vectors in gene therapy, visit @ AAV Vector Technology
Table of Contents
| 1. | AAV Vectors in Gene Therapy Pipeline Report Introduction |
| 2. | AAV Vectors in Gene Therapy Pipeline Report Executive Summary |
| 3. | AAV Vectors in Gene Therapy Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | AAV Vectors in Gene Therapy Clinical Trial Therapeutics |
| 6. | AAV Vectors in Gene Therapy Pipeline: Late Stage Products (Pre-registration) |
| 7. | AAV Vectors in Gene Therapy Pipeline: Late Stage Products (Phase III) |
| 8. | AAV Vectors in Gene Therapy Pipeline: Mid Stage Products (Phase II) |
| 9. | AAV Vectors in Gene Therapy Pipeline: Early Stage Products (Phase I) |
| 10. | AAV Vectors in Gene Therapy Pipeline Therapeutics Assessment |
| 11. | Inactive Products in the AAV Vectors in Gene Therapy Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the AAV Vectors in Gene Therapy Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the AAV vectors in gene therapy pipeline therapeutics, reach out @ AAV Vector Gene Therapy
Related Reports
Adeno-Associated Virus Vectors in Gene Therapy Market
Adeno-Associated Virus Vectors in Gene Therapy Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key adeno-associated virus vectors in gene therapy companies, including Pfizer, CSL Behring, Spark Therapeutics, Freeline Therapeutics, RegenxBio, Amicus Therapeutics, among others.
Gene Therapy In CNS Disorder Market
Gene Therapy In CNS Disorder Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key gene therapy In CNS disorder companies, including UniQure Biopharma, Brain Neurotherapy Bio, NeuroGeneration, Eli Lilly and Company, Sio Gene Therapies, among others.
Gene Therapy For Ocular Rare Disease Pipeline
Gene Therapy For Ocular Rare Disease Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key gene therapy for ocular rare disease companies, including Roche Holding, Novartis, Ocugen, among others.
Gene Therapies For Cardiomyopathies Pipeline
Gene Therapies For Cardiomyopathies Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key gene therapies for cardiomyopathies companies, including XyloCor Therapeutics, LEXEO Therapeutics, Stelios Therapeutics, Tenaya Therapeutics, Renova Therapeutics, among others.
Gene And Cell Therapies Targeting CNS Disorders Pipeline
Gene And Cell Therapies Targeting CNS Disorders Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key gene and cell therapies targeting CNS disorders companies, including UniQure Biopharma, Brain Neurotherapy Bio, NeuroGeneration, Eli Lilly and Company, Sio Gene Therapies, among others.
Other Trending Reports
Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Brain Cancer Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuroblastoma Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market
Related Healthcare Blogs
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
Artificial Intelligence
Wondershare DemoCreator Unveils V8.0: Accelerating Video Creation and Editing with Innovative AI Features
VANCOUVER, BC, May 28, 2024 /PRNewswire/ — Wondershare DemoCreator, the leading software for screen recording and video editing, proudly announces the release of its latest version DemoCreator 8.0. DemoCreator 8.0 supercharges the broad spectrum of educational and instructional video content, empowered by its updated AI enhancements. These advancements position DemoCreator 8.0 as a top player and pioneering video tool for educators, marketers, and influencers.
The PR Director at Wondershare, Iris L. stated, “DemoCreator has always been dedicated to simplifying video creation process, with version 8.0, we’ve introduced advanced AI technologies to enhance user experience and productivity. We believe that with our continuous effort, DemoCreator will remain the top choice for creators, helping them achieve greater success in sharing content.”
Key Upgrades in DemoCreator 8.0:
New Design: Upgraded UI and Magic Tools for enhanced efficiency.
New Template: Create captivating videos with refined templates in a few clicks.
Auto Subtitles: Generate accurate subtitles with trendy animations in over 90 languages.
Text to Speech: Convert text to human-like speech with 120+ voice options.
AI Voice Changer: Change voices into 24 different characters.
AI Object Remover: Remove unwanted elements from videos and images with one click.
AI Vocal Remover: Separate background sounds and vocals for noise reduction.
AI Beauty Filter: Six pre-set beauty effects with customization options.
Brand Kits: Create a unique brand kit with a customizable intro, outro, and logo.
Technological Upgrades: 50% faster video rendering and 200% faster export speeds.
Compatibility:
Wondershare DemoCreator is compatible with Windows and soon with Mac, with pricing starting at $29.99. For free trials and downloads, please visit DemoCreator’s website or follow us on YouTube, Facebook, Twitter, and Instagram to stay updated.
About Wondershare:
Wondershare is globally recognized as a software company committed to delivering innovative solutions for personal and professional use. As a leader in creativity and productivity products, Wondershare has received prestigious awards from organizations such as The Shorty Awards, G2, and GetApp. At Wondershare, the mission is to empower individuals to pursue their passions and build a more creative world. With over 100 million users across 150 countries, users can access a wide range of software solutions for video editing, PDF editing, data recovery, diagram and mind mapping, and more. Wondershare strives to provide high-quality, user-friendly software that enables individuals and businesses to bring their creative ideas to life.
Media Contacts
Iris [email protected]
Photo – https://mma.prnewswire.com/media/2422854/Wondershare.jpg
Logo – https://mma.prnewswire.com/media/1274391/wondershare_LOGO.jpg
View original content:https://www.prnewswire.co.uk/news-releases/wondershare-democreator-unveils-v8-0-accelerating-video-creation-and-editing-with-innovative-ai-features-302156318.html
Artificial Intelligence
Fingerprint Sensor Market worth $5.9 billion by 2029 – Exclusive Report by MarketsandMarkets™
CHICAGO, May 27, 2024 /PRNewswire/ — The Fingerprint Sensor Market is projected to grow from USD 4.2 billion in 2024 and is estimated to reach USD 5.9 billion by 2029; it is expected to grow at a Compound Annual Growth Rate (CAGR) of 7.0% from 2024 to 2029 according to a new report by MarketsandMarkets™. The rise in number of identity threats is one of the key factors leading to emergence of fingerprint technologies. Identity theft refers to the illegal acquisition of an individual’s personal or financial details to perpetrate fraud, including unauthorized transactions. It occurs through various methods and inflicts harm on victims’ credit, finances, and reputation.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=169519533
Browse in-depth TOC on “Fingerprint Sensor Market” 100 – Tables60 – Figures200 – Pages
Fingerprint Sensor Market Report Scope:
Report Coverage
Details
Market Revenue in 2024
$ 4.2 billion in 2024
Estimated Value by 2029
$ 5.9 billion
Growth Rate
Poised to grow at a CAGR of 7.0%
Market Size Available for
2020–2029
Forecast Period
2024–2029
Forecast Units
Value (USD Million/Billion)
Report Coverage
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered
By technology, sensor technology, type, end-use application and Region
Geographies Covered
North America, Europe, Asia Pacific, and Rest of World
Key Market Challenge
Sensor performance limitations
Key Market Opportunities
Increased adoption of IoT-based biometric technology
Key Market Drivers
Rise in number of identity threats leading to emergence of fingerprint technologies
Area & Touch sensors in the sensor type segment is expected to witness higher CAGR during the forecast period.
Area & touch sensors segment is expected to witness a higher CAGR during the forecast period in the fingerprint sensor market. These sensors activate upon physical contact with an object or individual and are more sensitive compared to traditional buttons or manual controls. They provide users with a seamless and responsive experience, making them ideal for modern electronic devices where sleek design and user convenience are paramount.
The 2D segment in the fingerprint sensor market is expected to capture higher share during the forecast period.
2D sensor technology captures a person’s fingerprint pattern, including ridges and valleys, in two dimensions using a single plane of lasers to measure the X and Y dimensions. This technology is primarily utilized for detection and ranging tasks. Due to its affordability, 2D sensor technology remains popular among OEMs, especially in mobile devices requiring compact sensors to meet the preferences of end users. Key players such as Synaptics Incorporated (US), Fingerprints (Sweden), and Shenzhen Goodix Technology Co., Ltd. (China) offer 2D sensors for various consumer electronics and applications.
Ultrasonic is expected to witness the highest CAGR in the fingerprint sensor market during the forecast period.
Ultrasonic fingerprint sensors utilize sound waves to penetrate the outer layers of the skin, enabling the capture of three-dimensional (3D) details and distinct fingerprint characteristics like ridges and sweat pores. Unlike current capacitive touch-based fingerprint technologies, ultrasonic sensors can read both the epidermal and dermal layers of the skin, allowing for the capture of fine details. Consequently, these sensors can accurately read wet fingers or those with ruptured or damaged skin. The continuous advancements in sensing technology are expected anticipated to propel the growth of the ultrasonic fingerprint sensor market. In January 2022, vivo (China) announced the 1000 9 Pro smartphone with Qualcomm’s 3D Sonic Max ultrasonic fingerprint sensor. The new smartphone is based on Snapdragon 8 Gen 1 processor. The Qualcomm 3D Sonic Max in the IQ00 9 Pro enables a super-fast one-tap fingerprint registration process.
Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=169519533
North America is expected to hold the second largest share of the fingerprint sensor industry during the forecast period.
North America is driven by the increasing adoption of biometric authentication across various sectors, particularly consumer electronics, government, and commercial domains. The US Department of Homeland Security (DHS) has been actively promoting the use of biometric technologies, including fingerprint sensors, for enhancing border security and immigration processes. The DHS’s Biometric Entry-Exit Program has facilitated the deployment of fingerprint scanners at various ports of entry, contributing to the market’s growth in the region. According to November 2023 statistics by US Department of Homeland Security (DHS), 1,018,349 persons obtained lawful permanent resident status in year 2022 compared to 740,002 persons in 2021, which is 37.6% y-o-y increase.
Key Players
Major vendors in the fingerprint sensor companies include Shenzhen Goodix Technology Co., Ltd. (China), Fingerprints (Sweden), Synaptics Incorporated (US), Apple Inc. (US) NEXT Biometrics (Norway), Novatek Microelectronics Corp. (Taiwan), Qualcomm Technologies, Inc. (US) among others.
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=169519533
Browse Adjacent Market: Semiconductor and Electronics Market Research Reports &Consulting
Related Reports:
Access Control Market by Offering (Hardware-Card-based, Biometric, & Multi-technology Readers, Electronics Locks, Controllers; Software; Services), ACaaS (Hosted, Managed, Hybrid), Vertical and Region – Global Forecast to 2029
Biometric System Market Size, Share & Industry Growth Analysis Report by Authentication Type (Single Factor, Fingerprint, Iris, Face, Voice; Multi-factor), Type (Contact-based, Contactless, Hybrid), Offering Type, Mobility, Vertical & Region, 2027
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Contact: Mr. Aashish MehraMarketsandMarkets™ INC. 630 Dundee RoadSuite 430Northbrook, IL 60062USA: +1-888-600-6441Email: [email protected] Our Web Site: https://www.marketsandmarkets.com/Research Insight: https://www.marketsandmarkets.com/ResearchInsight/fingerprint-sensors-market.aspContent Source: https://www.marketsandmarkets.com/PressReleases/fingerprint-sensors.asp
Logo: https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg
View original content:https://www.prnewswire.co.uk/news-releases/fingerprint-sensor-market-worth-5-9-billion-by-2029—exclusive-report-by-marketsandmarkets-302155899.html
Artificial Intelligence
Cloud Analytics Market worth $118.5 billion by 2029- Exclusive Report by MarketsandMarkets™
CHICAGO, May 27, 2024 /PRNewswire/ — The market for cloud analytics has a promising future because of the acceptance of real-time analytics, the expansion of big data and IoT, and the integration of AI and machine learning. Its adoption across multiple industries will be further accelerated by improved security, edge computing integration, and user-friendly platforms that prioritise data-driven decision-making and customised customer experiences.
The Cloud Analytics Market is estimated to grow from USD 35.7 billion in 2024 to USD 118.5 billion in 2029, at a CAGR of 27.1% during the forecast period, according to a new report by MarketsandMarkets™. Cloud analytics revolutionizes data storage and analysis by harnessing the power of the cloud. By storing and analyzing data in the cloud, businesses can extract actionable insights crucial for both SMEs and large enterprises. This approach facilitates identifying patterns, predicting future outcomes, and gaining valuable insights. Cloud analytics offers an opportunity to consolidate data and convert it into actionable intelligence while reducing procurement and maintenance costs. It involves utilizing both cloud-stored data and the rapid computing power of the cloud for faster analytics. However, with cloud infrastructure, organizations gain access to scalable, secure, and efficient data storage and processing solutions, enabling them to meet the demands of big data and drive innovation.
Browse in-depth TOC on “Cloud Analytics Market”
333 – Tables 66 – Figures342 – Pages
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=959
Scope of the Report
Report Metrics
Details
Market size available for years
2019–2029
Base year considered
2023
Forecast period
2024–2029
Forecast units
USD Billion
Segments Covered
Offering, Data Type, Data Processing, Vertical, and Region
Geographies covered
North America, Europe, Asia Pacific, Middle East & Africa, and Latin America
Companies covered
IBM (US), SAS Institute (US), Oracle (US), Google (US), Microsoft (US), Teradata (US), Salesforce (US), AWS (US), NetApp (US), Qilk (US), Sisense (US), SAP (Germany), Atos (France), Altair (US), Microstrategy (US), Tibco Software (US), Hexaware Technologies (India), Zoho (India), Rackspace Technology (US), Splunk (US), Cloudera (US), Domo (US), Hewlett Packard Enterprise (US), Incorta (US), Tellius (US), Rapyder (US), Hitachi Vantara (US), Board International (Switzerland), Ridge (Israel), Jaspersoft (US), Yellowfin (Australia), Deonodo (US), GoodData (US), Thoughtspot (US), and Infogain (US)
By offering the services segment to account for higher CAGR during the forecast period
Services segment in the Cloud Analytics Market have experienced remarkable growth in the Cloud Analytics Market, fueled by the increasing adoption of data-driven decision-making across industries. These services offer businesses the capability to analyze vast amounts of data stored in the cloud swiftly and efficiently, enabling them to extract valuable insights for strategic planning, optimization, and innovation. With the scalability and flexibility of cloud infrastructure, analytics services can accommodate diverse data types and analytical workloads, empowering organizations to derive actionable intelligence from their data in real time. As businesses continue to prioritize agility and competitiveness, the demand for cloud analytics services is expected to soar, driving further innovation and expansion in the Cloud Analytics Market landscape.
Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=959
By Type, advanced analytics solution is expected to hold the largest market size for the year 2024
The surge in advanced analytics adoption within the Cloud Analytics Market is reshaping the landscape of data-driven decision-making. Organizations across diverse sectors are increasingly turning to advanced analytics solutions hosted on cloud platforms to extract deeper insights from their data. This trend stems from the growing realization that traditional analytics methods are no longer sufficient to cope with the complexities of modern data ecosystems. Advanced analytics, powered by machine learning algorithms, predictive modeling, and AI, offer unparalleled capabilities to uncover hidden patterns, forecast trends, and optimize business processes. By leveraging the scalability, flexibility, and cost-effectiveness of cloud infrastructure, businesses can access powerful analytics tools without the burden of hefty upfront investments in hardware and software. As a result, the Cloud Analytics Market is witnessing rapid expansion, fueled by the transformative potential of advanced analytics in driving innovation, enhancing operational efficiency, and gaining a competitive edge in today’s data-driven economy.
By Vertical, Healthcare & Life Sciences is projected to grow at the highest CAGR during the forecast period
The healthcare and life sciences sector is experiencing a transformative shift with the emergence of cloud analytics. This technology integrates vast amounts of data from various sources, including electronic health records, wearable devices, and genomic information, to derive meaningful insights and drive informed decision-making. Cloud analytics offers scalability, flexibility, and cost-effectiveness, enabling organizations to efficiently manage and analyze massive datasets that were previously challenging to handle. By leveraging advanced analytics techniques such as machine learning and predictive modeling, healthcare providers and life sciences companies can enhance patient care, optimize clinical workflows, and accelerate drug discovery processes. Moreover, cloud-based analytics facilitates collaboration among researchers, clinicians, and stakeholders, fostering innovation and driving advancements in personalized medicine and population health management. As the industry continues to embrace digital transformation, cloud analytics stands as a cornerstone for unlocking the full potential of data-driven healthcare and life sciences initiatives.
Asia Pacific is expected to grow at the highest CAGR during the forecast period
The Asia Pacific region is experiencing a significant surge in the adoption of cloud analytics, reshaping how businesses make data-driven decisions. Companies spanning various industries are embracing cloud-based analytics platforms to optimize operations, foster innovation, and gain actionable insights. Additionally, the ubiquitous nature of mobile devices and internet connectivity has heightened the demand for real-time analytics accessible from anywhere. Governments and enterprises recognize the strategic value of harnessing analytics to maintain competitiveness in the global marketplace. Consequently, investments in cloud analytics technologies and talent development are escalating, positioning the Asia Pacific region as a pivotal player in the global cloud analytics landscape.
Top Key Companies in Cloud Analytics Market:
The significant cloud analytics software and service providers include IBM (US), SAS Institute (US), Oracle (US), Google (US), Microsoft (US), Teradata (US), Salesforce (US), AWS (US), NetApp(US), Qilk(US), Sisense (US), SAP (Germany), Atos (France), Altair (US), Microstrategy (US), Tibco Software (US), Hexaware Technologies (India), Zoho (India), Rackspace Technology (US), Splunk (US), Cloudera (US), Domo (US), Hewlett Packard Enterprise (US), Incorta (US), Tellius (US), Rapyder (US), Hitachi Vantara (US), Board International (Switzerland), Ridge (Israel), Jaspersoft (US), Yellowfin (Australia), Deonodo(US), GoodData(US), Thoughtspot (US), and Infogain (US). These companies have used organic and inorganic growth strategies such as product launches, acquisitions, and partnerships to strengthen their position in the Cloud Analytics Market.
Recent Developments:
In January 2024, Salesforce unveiled fresh Commerce Cloud tools leveraging generative AI and data-driven insights, enhancing every customer interaction for heightened loyalty and revenue growth.In February 2024, IBM and Wipro strengthened their collaboration to offer clients expanded AI services and support. This collaboration aims to utilize AI technologies to tackle various business challenges and foster innovation across industries.In June 2023, Salesforce and Google formed a partnership. The partnership between Salesforce and Google focuses on integrating Google’s AI capabilities into Salesforce’s products, enhancing their analytics offerings.In May 2023, Microsoft launched Microsoft Fabric Data Analytics which is a cutting-edge platform tailored for the AI era, facilitating seamless integration of analytics and AI capabilities into data processing workflows. It streamlines data ingestion, preparation, and analysis, enabling organizations to derive actionable insights efficiently.In August 2022, Teradata introduced VantageCloud Lake, a cloud-native service designed to simplify data lakes for businesses, enabling seamless management and analytics of vast data sets.Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=959
Cloud Analytics Market Advantages:
Platforms for cloud analytics offer scalable resources, making it simple for companies to modify their requirements for storage and processing power in response to demand. Because of its adaptability, businesses may manage different data volumes without having to make costly infrastructure investments.Businesses can lower their capital hardware and software costs by utilising cloud analytics. Pay-as-you-go cloud service pricing allows businesses to optimise their total IT expenditure by only paying for the resources they really utilise.Compared to on-premises systems, cloud analytics solutions may be implemented and deployed far more quickly. This speedy deployment shortens the time to insight, allowing companies to begin data analysis and value extraction right away.Platforms for cloud-based analytics enable remote access to analytics tools and data from any location with an internet connection. Team members can collaborate on data projects regardless of location thanks to this accessibility, which fosters teamwork.Advanced analytics features like machine learning, artificial intelligence, and predictive analytics are frequently included in cloud analytics solutions. Organisations can gain deeper insights and make better decisions with the aid of these technologies.Businesses can analyse data as it is generated with the use of cloud analytics solutions, which provide real-time data processing and analytics. Applications that need instant insights, like fraud detection, operational monitoring, and customer engagement, depend on this real-time capacity.Platforms for cloud analytics can easily interface with a range of data sources, such as databases, data lakes, outside apps, and Internet of Things gadgets. A unified perspective of corporate operations and thorough data analysis are guaranteed by this integration capabilities.Report Objectives
To define, describe, and predict the Cloud Analytics Market by offering, data type, data processing, vertical, and regionTo describe and forecast the Cloud Analytics Market, in terms of value, by region—North America, Europe, Asia Pacific, Middle East & Africa, and Latin AmericaTo provide detailed information regarding major factors influencing the market growth (drivers, restraints, opportunities, and challenges)To strategically analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall Cloud Analytics MarketTo profile key players and comprehensively analyze their market positions in terms of ranking and core competencies, along with detailing the competitive landscape for market leadersTo analyze competitive developments such as joint ventures, mergers and acquisitions, product developments, and ongoing research and development (R&D) in the Cloud Analytics MarketTo provide the illustrative segmentation, analysis, and projection of the main regional marketsBrowse Adjacent Markets: Analytics Market Research Reports & Consulting
Related Reports:
Risk Analytics Market – Global Forecast to 2029
Retail Analytics Market- Global Forecast to 2029
Text to Video AI Market – Global Forecast to 2027
Contact Center Analytics Market- Global Forecast to 2027
Procurement Analytics Market- Global Forecast to 2026
Get access to the latest updates on Cloud Analytics Companies and Cloud Analytics Industry
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Contact:Mr. Aashish MehraMarketsandMarkets™ INC. 630 Dundee Road Suite 430Northbrook, IL 60062USA: +1-888-600-6441Email: [email protected] Our Website: https://www.marketsandmarkets.com/
Logo: https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg
View original content:https://www.prnewswire.co.uk/news-releases/cloud-analytics-market-worth-118-5-billion-by-2029–exclusive-report-by-marketsandmarkets-302155868.html
-
Artificial Intelligence4 days agoTitans of Tech: GP Bullhound releases its annual report on the European tech ecosystem
-
Uncategorized4 days agoGienTech Hosted the “2024 GienTech Digital Transformation Conference” to Promote Overseas Collaborative Ecosystem Development
-
Artificial Intelligence4 days agoBybit Web3 Announces Upcoming IDO for Aperture Finance, Simplifying Web3 Finance
-
Uncategorized4 days ago
Hyreo ushers in a New Dawn for Recruitment Technology with Hyreo Labs
-
Artificial Intelligence6 days agoHONOR Unveils Four-Layer AI Architecture and Forges Ahead with Google Cloud for More AI Experiences at VivaTech 2024
-
Artificial Intelligence4 days agoNorthern Data Group’s Peak Mining, announces purchase of a second 300MW data center location in Corpus Christi, Texas
-
Artificial Intelligence3 days agoIoT Node and Gateway Market worth $604.7 billion by 2029 – Exclusive Report by MarketsandMarkets™
-
Artificial Intelligence3 days agoOverseas Expansion Strategy of K-OTT Introduced in France, KOCCA holds the ‘2024 Korea-France Content Forum’
